Trulicity
Eli Lilly’s Trulicity approved in US to reduce cardiovascular events in type 2 diabetes patients
February 24, 2020Sales and Marketing Eli Lilly, Trulicity, cardiovascular disease, pharma
Eli Lilly’s Trulicity (duraglutide) has been awarded marketing authorisation from the FDA as a therapy to reduce major adverse cardiovascular …
Eli Lilly’s heart drug underwhelms with REWIND trial
June 11, 2019Manufacturing and Production Eli Lilly, Trulicity, pharma
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according …
Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes
November 7, 2018Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes
Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …
Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2
June 25, 2018Research and Development, Sales and Marketing Eli Lilly, Trulicity, diabetes, pharma
Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
